Antibodies and Inhibitors for Cancer Research

Antibodies used in this study are as follows: tubulin (#T5168) and Flag (#F3165) were purchased from Sigma-Aldrich (St. Louis, MO); PARP1 (#sc-7150) for Western blotting from Santa Cruz Biotechnology (Santa Cruz, CA); PARP1 (#9532) for immunoprecipitation (IP), MET (#8198), phosphorylated MET (#3077), phosphorylated EGFR for IHC (#3777) and EGFR (#4267) from Cell Signaling Technology (Danvers, MA); and phosphorylated EGFR for Western blotting (#5650), Ki67 (#21700), cleaved caspase 3 (#2302), γ-H2AX (#140498), and PAR (#14460) from Abcam (Cambridge, MA); 8-hydroxy-2′-deoxy guanosine (8-OHdG) from Genox Corporation (Baltimore, MD). The mouse phospho-Y907-PARP1 antibody was generated against a phosphorylated synthetic peptide (ADMVSKSAN-Yp-CHTSQGD) at China Medical University as described previously (13 (link)). The following inhibitors were used in this study: MET kinase inhibitor crizotinib (#C-7900) was purchased from LC Laboratories (Woburn, MA); EGFR inhibitor gefitinib (#S1025) and erlotinib (#S1023) from Selleck Chemicals (Houston, TX); PARP inhibitors ABT-888 (veliparib, #CT-A888) and AG014699 (rucaparib, #CT-AG01) from ChemieTek (Indianapolis, IN). Hydrogen peroxide (#216763) and sodium arsenite solution (#35000) were obtained from Sigma-Aldrich.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Dong Q., Du Y., Li H., Liu C., Wei Y., Chen M.K., Zhao X., Chu Y.Y., Qiu Y., Qin L., Yamaguchi H, & Hung M.C. (2018). EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma. Cancer research, 79(4), 819-829.

Publication 2018

tubulin Flag PARP1 phosphorylated MET cleaved caspase 3 γ-H2AX crizotinib gefitinib erlotinib ABT-888 veliparib AG014699 rucaparib Hydrogen peroxide sodium arsenite solution

8 ohdg Abt 888 Ag014699 Antibodies Antibody Caspase 3 Crizotinib Deoxy Egfr Erlotinib Gefitinib Guanosine Hydrogen peroxide Immunoprecipitation Inhibitors Kinase Mouse parp1 Parp inhibitors Parp1 Peptide Rucaparib Sodium arsenite Tubulin Veliparib

Corresponding Organization : China Medical University

Other organizations : Fudan University, Huashan Hospital, Zhongshan Hospital

Top 5 similar protocols

Variable analysis

independent variables

MET kinase inhibitor crizotinib
EGFR inhibitor gefitinib
EGFR inhibitor erlotinib
PARP inhibitors ABT-888 (veliparib)
PARP inhibitors AG014699 (rucaparib)
Hydrogen peroxide
Sodium arsenite solution

dependent variables

PARP1 expression (Western blotting and IP)
MET phosphorylation
EGFR phosphorylation (Western blotting and IHC)
Cell proliferation (Ki67)
Apoptosis (cleaved caspase 3)
DNA damage (γ-H2AX)
Oxidative stress (8-OHdG)
PAR levels

control variables

Tubulin

positive controls

Mouse phospho-Y907-PARP1 antibody

negative controls

Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!